Geron of Menlo Park, California, plans to raise $72 million from a new stock offering. About $18 million of that will come as a direct investment from Merck, which inked a collaboration deal with Geron July 15. Look for much of the money to go into its research into telomerase, an enzyme that plays a role in protecting cells and may help as a therapy for cancer and damaged tissue. Geron is also studying uses of embryonic stem cells in treating disease.
- read this story from The San Jose Business Journal for more
ALSO: Myogen plans an offering of 4.7 million shares to raise $101 million. The biotech company is researching two blood pressure products. Report